首页> Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology> Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.

Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.

导出 OA

翻译打印收藏纠错

第一作者： Werner,Aberer

第一单位： Department of Dermatology and Venerology, Medical University of Graz, Auenbruggerplatz 8, A-8036 Graz, Austria.

作者： Werner,Aberer ^[1] ; Marcus,Maurer ^[2] ; Laurence,Bouillet ^[3] ; Andrea,Zanichelli ^[4] ; Teresa,Caballero ^[5] ; Hilary J,Longhurst ^[6] ; Amandine,Perrin ^[7] ; Irmgard,Andresen ^[7] ; IOS Study Group

作者单位： Department of Dermatology and Venerology, Medical University of Graz, Auenbruggerplatz 8, A-8036 Graz, Austria. ^[1] Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany. ^[2] National Reference Centre for Angioedema, Internal Medicine Department, Grenoble University Hospital, Boulevard de la Chantourne-CS10217, 38043 Grenoble, France. ^[3] Department of Biomedical and Clinical Sciences Luigi Sacco, ASST Fatebenefratelli Sacco, University of Milan, Via G.B. Grassi 74, 20157 Milan, Italy. ^[4] Allergy Department, Hospital La Paz Institute for Health Research (IdiPaz), Biomedical Research Network on Rare Diseases (CIBERER, U754), Paseo de la Castellana 261, 28046 Madrid, Spain. ^[5] Department of Immunology, Barts Health NHS Trust, 80 Newark Street, London, E1 2ES UK. ^[6] Shire, Zählerweg 10, 6300 Zug, Switzerland. ^[7]

关键词 Bradykinin Breakthrough attacks Hereditary angioedema Icatibant Prophylaxis

DOI 10.1186/s13223-017-0203-z

PMID 28690642

发布时间 2020-09-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交